Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 07 2020
14 07 2020
Historique:
received:
26
11
2019
accepted:
29
05
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Identification of biomarkers associated with protection from developing diabetic complications is a prerequisite for an effective prevention and treatment. The aim of the present study was to identify clinical and plasma metabolite markers associated with freedom from vascular complications in people with very long duration of type 1 diabetes (T1D). Individuals with T1D, who despite having longer than 30 years of diabetes duration never developed major macro- or microvascular complications (non-progressors; NP) were compared with those who developed vascular complications within 25 years from diabetes onset (rapid progressors; RP) in the Scandinavian PROLONG (n = 385) and DIALONG (n = 71) cohorts. The DIALONG study also included 75 healthy controls. Plasma metabolites were measured using gas and/or liquid chromatography coupled to mass spectrometry. Lower hepatic fatty liver indices were significant common feature characterized NPs in both studies. Higher insulin sensitivity and residual ß-cell function (C-peptide) were also associated with NPs in PROLONG. Protection from diabetic complications was associated with lower levels of the glycolytic metabolite pyruvate and APOCIII in PROLONG, and with lower levels of thiamine monophosphate and erythritol, a cofactor and intermediate product in the pentose phosphate pathway as well as higher phenylalanine, glycine and serine in DIALONG. Furthermore, T1D individuals showed elevated levels of picolinic acid as compared to the healthy individuals. The present findings suggest a potential beneficial shunting of glycolytic substrates towards the pentose phosphate and one carbon metabolism pathways to promote nucleotide biosynthesis in the liver. These processes might be linked to higher insulin sensitivity and lower liver fat content, and might represent a mechanism for protection from vascular complications in individuals with long-term T1D.
Identifiants
pubmed: 32665614
doi: 10.1038/s41598-020-68130-y
pii: 10.1038/s41598-020-68130-y
pmc: PMC7360755
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
C-Peptide
0
Nucleotides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11561Références
Jacobson, A. M. et al. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care 36, 3131–3138 (2013).
pubmed: 23835693
pmcid: 3781542
Ortiz, F. et al. Long-term mortality after kidney transplantation in a nationwide cohort of patients with type 1 diabetes in Finland. Diabetes Care 42, 55–61 (2019).
pubmed: 30389672
List of countries by incidence of Type 1 diabetes ages 0–14. Diabetes UK https://www.diabetes.org.uk/about_us/news_landing_page/uk-has-worlds-5th-highest-rate-of-type-1-diabetes-in-children/list-of-countries-by-incidence-of-type-1-diabetes-ages-0-to-14 .
Pathak, V., Pathak, N. M., O’Neill, C. L., Guduric-Fuchs, J. & Medina, R. J. Therapies for type 1 diabetes: current scenario and future perspectives. Clin. Med. Insights Endocrinol. Diabetes 12, 1179551419844521 (2019).
pubmed: 31105434
pmcid: 6501476
Heilig, C. W. et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J. Clin. Invest. 96, 1802–1814 (1995).
pubmed: 7560072
pmcid: 185817
Kaiser, N. et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42, 80–89 (1993).
pubmed: 7678404
Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005).
pubmed: 15919781
Holte, K. B. et al. Hand, shoulder and back stiffness in long-term type 1 diabetes; cross-sectional association with skin collagen advanced glycation end-products. The Dialong study. J. Diabetes Complicat. 31, 1408–1414 (2017).
pubmed: 28705609
Svanteson, M., Holte, K. B., Haig, Y., Kløw, N. E. & Berg, T. J. Coronary plaque characteristics and epicardial fat tissue in long term survivors of type 1 diabetes identified by coronary computed tomography angiography. Cardiovasc. Diabetol. 18, 58 (2019).
pubmed: 31054573
pmcid: 6500584
Singh, A., Le, P., Lopez, R. & Alkhouri, N. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients. Hepatol. Int. 12, 37–43 (2018).
pubmed: 29318450
Mantovani, A. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int. J. Cardiol. 225, 387–391 (2016).
pubmed: 27768965
Mantovani, A. et al. Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. J. Diabetes Complicat. 31, 1021–1026 (2017).
pubmed: 28254449
Targher, G. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 37, 1729–1736 (2014).
pubmed: 24696459
Cleland, S. J., Fisher, B. M., Colhoun, H. M., Sattar, N. & Petrie, J. R. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?. Diabetologia 56, 1462–1470 (2013).
pubmed: 23613085
pmcid: 3671104
Bain, S. C. et al. Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet. Med. J. Br. Diabet. Assoc. 20, 808–811 (2003).
Gill, G. V., Daousi, C., Barnett, A. H. & Bain, S. C. Chronic kidney disease in long duration type 1 diabetes lasting more than 50 years. Curr. Med. Res. Opin. 25, 395–400 (2009).
pubmed: 19192984
Gordin, D. et al. Arterial stiffness and vascular complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) Study. Ann. Med. 44, 196–204 (2012).
pubmed: 21047152
Madsen, C. M., Varbo, A. & Nordestgaard, B. G. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur. Heart J. 38, 2478–2486 (2017).
pubmed: 28419274
Mardinoglu, A. et al. Personal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD. Mol. Syst. Biol. 13, 916 (2017).
pubmed: 28254760
pmcid: 5371732
Mardinoglu, A. et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 3083 (2014).
pubmed: 24419221
Amelio, I., Cutruzzolá, F., Antonov, A., Agostini, M. & Melino, G. Serine and glycine metabolism in cancer. Trends Biochem. Sci. 39, 191–198 (2014).
pubmed: 24657017
pmcid: 3989988
Luukkonen, P. K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 64, 1167–1175 (2016).
pubmed: 26780287
Chen, L. et al. NADPH production by the oxidative pentose-phosphate pathway supports folate metabolism. Nat. Metab. 1, 404–415 (2019).
pubmed: 31058257
pmcid: 6489125
Connell, N. J., Houtkooper, R. H. & Schrauwen, P. NAD+ metabolism as a target for metabolic health: have we found the silver bullet?. Diabetologia 62, 888–899 (2019).
pubmed: 30772929
pmcid: 6509089
Beltramo, E., Berrone, E., Tarallo, S. & Porta, M. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol. 45, 131–141 (2008).
pubmed: 18581039
Thornalley, P. J. et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 50, 2164–2170 (2007).
pubmed: 17676306
pmcid: 1998885
Du, X., Edelstein, D. & Brownlee, M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 51, 1930–1932 (2008).
pubmed: 18663426
Hammes, H.-P. et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9, 294–299 (2003).
pubmed: 12592403
Fraser, D. A. et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 35, 1095–1097 (2012).
pubmed: 22446172
pmcid: 3329837
Pan, X. et al. Long-term cognitive improvement after benfotiamine administration in patients with Alzheimer’s disease. Neurosci. Bull. 32, 591–596 (2016).
pubmed: 27696179
pmcid: 5567484
Bloomgarden, Z. Diabetes and branched-chain amino acids: What is the link?. J. Diabetes 10, 350–352 (2018).
pubmed: 29369529
Hootman, K. C. et al. Erythritol is a pentose-phosphate pathway metabolite and associated with adiposity gain in young adults. Proc. Natl. Acad. Sci. USA 114, E4233–E4240 (2017).
pubmed: 28484010
Rebholz, C. M. et al. Serum metabolomic profile of incident diabetes. Diabetologia 61, 1046–1054 (2018).
pubmed: 29556673
pmcid: 5878141
Chen, L. et al. Plasma metabonomic profiling of diabetic retinopathy. Diabetes 65, 1099–1108 (2016).
pubmed: 26822086
Haukka, J. K. et al. Metabolomic profile predicts development of microalbuminuria in individuals with type 1 diabetes. Sci. Rep. 8, 13853 (2018).
pubmed: 30217994
pmcid: 6138633
Yuan, M. et al. An allostatic mechanism for M2 pyruvate kinase as an amino-acid sensor. Biochem. J. 475, 1821–1837 (2018).
pubmed: 29748232
pmcid: 5980995
Qi, W. et al. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat. Med. 23, 753–762 (2017).
pubmed: 28436957
pmcid: 5575773
Gordin, D. et al. Characterization of glycolytic enzymes and pyruvate kinase m2 in type 1 and 2 diabetic nephropathy. Diabetes Care https://doi.org/10.2337/dc18-2585 (2019).
doi: 10.2337/dc18-2585
pubmed: 31076418
pmcid: 6609957
Galderisi, A. et al. Metabolomics reveals new metabolic perturbations in children with type 1 diabetes. Pediatr. Diabetes 19, 59–67 (2018).
pubmed: 28401628
Mazaika, P. K. et al. Variations in brain volume and growth in young children with type 1 diabetes. Diabetes 65, 476–485 (2016).
pubmed: 26512024
Braidy, N., Guillemin, G. J. & Grant, R. Effects of Kynurenine pathway inhibition on NAD+ metabolism and cell viability in human primary astrocytes and neurons. Int. J. Tryptophan Res. IJTR 4, 29–37 (2011).
pubmed: 22084601
Grant, R., Nguyen, S. & Guillemin, G. Kynurenine pathway metabolism is involved in the maintenance of the intracellular NAD+ concentration in human primary astrocytes. Int. J. Tryptophan Res. IJTR 3, 151–156 (2010).
pubmed: 22084595
Rajman, L., Chwalek, K. & Sinclair, D. A. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 27, 529–547 (2018).
pubmed: 29514064
pmcid: 6342515
Grant, R. S., Coggan, S. E. & Smythe, G. A. The physiological action of picolinic acid in the human brain. Int. J. Tryptophan Res. IJTR 2, 71–79 (2009).
pubmed: 22084583
Weber, G. et al. Regulation of purine and pyrimidine metabolism by insulin and by resistance to tiazofurin. Adv. Enzyme Regul. 23, 81–99 (1985).
pubmed: 3907307
Marchesini, G. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450–455 (1999).
pubmed: 10569299
ter Horst, K. W. et al. Hepatic diacylglycerol-associated protein kinase Cε translocation links hepatic steatosis to hepatic insulin resistance in humans. Cell Rep. 19, 1997–2004 (2017).
pubmed: 28591572
pmcid: 5469939
Perseghin, G. et al. Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes. Diabetologia 48, 2615–2621 (2005).
pubmed: 16261312
Llauradó, G. et al. Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 100, 607–616 (2015).
pubmed: 25405502
Nyström, T., Holzmann, M. J., Eliasson, B., Svensson, A.-M. & Sartipy, U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes. Metab. 20, 556–563 (2018).
pubmed: 28884949
Marren, S. M. et al. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA1c in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabet. Med. J. Br. Diabet. Assoc. https://doi.org/10.1111/dme.13960 (2019).
doi: 10.1111/dme.13960
Dallio, M. et al. Endocan serum levels in patients with non-alcoholic fatty liver disease with or without type 2 diabetes mellitus: a pilot study. J. Gastrointest. Liver Dis. JGLD 26, 261–268 (2017).
Ludvigsson, J. F. et al. External review and validation of the Swedish national inpatient register. BMC Public Health 11, 450 (2011).
pubmed: 21658213
pmcid: 3142234
Bang, P., Eriksson, U., Sara, V., Wivall, I. L. & Hall, K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol. (Copenh.) 124, 620–629 (1991).
Póvoa, G., Roovete, A. & Hall, K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol. (Copenh.) 107, 563–570 (1984).
Williams, K. V., Erbey, J. R., Becker, D., Arslanian, S. & Orchard, T. J. Can clinical factors estimate insulin resistance in type 1 diabetes?. Diabetes 49, 626–632 (2000).
pubmed: 10871201
Lee, J.-H. et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 42, 503–508 (2010).
Sviklāne, L. et al. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J. Gastroenterol. Hepatol. 33, 270–276 (2018).
pubmed: 28464337
Spégel, P. et al. Metabolomic analysis of a human oral glucose tolerance test reveals fatty acids as reliable indicators of regulated metabolism. Metabolomics 6, 56–66 (2010).
Spégel, P. et al. Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2). Diabetes 62, 653–661 (2013).
pubmed: 23139355
pmcid: 3554352
Wuolikainen, A. et al. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson’s disease and control subjects. Mol. Biosyst. 12, 1287–1298 (2016).
pubmed: 26883206
Chorell, E., Moritz, T., Branth, S., Antti, H. & Svensson, M. B. Predictive metabolomics evaluation of nutrition-modulated metabolic stress responses in human blood serum during the early recovery phase of strenuous physical exercise. J. Proteome Res. 8, 2966–2977 (2009).
pubmed: 19317510
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882–883 (2012).
pubmed: 3307112
pmcid: 3307112
Leys, C., Ley, C., Klein, O., Bernard, P. & Licata, L. Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median. J. Exp. Soc. Psychol. 49, 764–766 (2013).